Dr. Marincola will lead Kite’s Research organization across hematological malignancies and solid tumors. Kite Pharma Santa Monica, CA. Apply on company website Save. 81 Kite Pharma jobs available in Santa Monica, CA on Indeed.com. [36], In May 2013, Kite Pharma completed a $35 million financing of Series A preferred stock. [43][44][45] The company listed on the NASDAQ Global market under the symbol “KITE.”, In December 2014, Kite Pharma sold 4,007,750 shares of it common stock in their follow-on offering at $54.00 per share, for gross proceeds of $216.4 million. More... - Graduate Intern, Commercial Operations - Marketing new. [30], In July, Kite Pharma announced that it has entered into an exclusive, worldwide license agreement with The Regents of the University of California, on behalf of the University of California, Los Angeles (UCLA), for technology to advance the development of off-the-shelf allogeneic T-cell therapies from renewable pluripotent stem cells. Alle Fotos anzeigen Alle anzeigen. All content is posted anonymously by employees working at Kite Pharma. About Gilead Sciences. [1] Belldegrun had a co-founder in Joshua Kazam, who took on the role of Director. Kite is a Trademark by Kite Pharma, Inc., the address on file for this trademark is 2225 Colorado Ave., Santa Monica, CA 90404 [13], In June, Kite Pharma entered into an exclusive, worldwide license with the National Institutes of Health (NIH) to certain intellectual property related to TCR-based product candidates that target the NY-ESO-1 antigen for the treatment of cancers expressing NY-ESO-1. Search 55 Kite Pharma jobs in Santa Monica Ca at Ladders. Kite Pharma Santa Monica, CA Just now Be among the first 25 applicants. 2400 Broadway Share a Photo. Glassdoor gives you an inside look at what it's like to work at Kite Pharma, including salaries, reviews, office photos, and more. [46], In March 2015, Kite Pharma acquired T-Cell Factory (TCF), a privately held biotechnology company based in the Netherlands, for €20 million and renamed it – Kite Pharma EU. Together, the parties will design and develop a platform for patients, physicians and treatment centers that enables commercial-scale ordering, logistics, monitoring and delivery of autologous cell therapies if they are FDA-approved, including axicabtagene ciloleucel (formerly known as KTE-C19), Kite’s lead investigational engineered T-cell therapy for aggressive non-Hodgkin lymphoma. Receive alerts for 300+ data fields across thousands of companies. Kite Pharma, a subsidiary of Gilead Sciences, develops cancer immunotherapy products with a primary focus on genetically engineered autologous T cell therapy with chimeric antigen receptors (CAR-T). [16][17], In May, Kite Pharma announced that the first patient in its Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive Non-Hodgkin's Lymphoma has been treated. Kite Pharma • Santa Monica, CA 90401 (LOS ANGELES County) and 4 other locations Selecting best-suited partner (excluding Strategic Partnerships) to meet Kite's strategic objectives... Posted 1w ago Kite Pharma, Inc. What's it like to work here? [7], Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)) in which a patient's T cells were genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. See who Kite Pharma has hired for this role . Cancer research firm Kite Pharma is paying $135 million for a 160,000-square-foot research and development building in Santa Monica, adding to … 74 Jobs für kite. The target population for the tests would be patients suffering from non-Hodgkin Lymphoma. Upload a resume to easily apply to jobs from anywhere. Reviews (310) 824-9999 Website. This collaboration will accelerate Kite's efforts to establish the next generation of engineered T cell therapies specifically designed to overcome the inhibitory mechanisms present in the tumor microenvironment. Kite has been at the forefront of cancer immunotherapy since 2009. (310) 824-9999 Jan. 2021. Kite is engaged in the development of innovative cancer immunotherapies. Find the Kite Pharma Santa Monica address. [18], In June, Kite Pharma and bluebird bio, Inc. announced they have entered into a collaboration agreement to co-develop and co-commercialize second generation T cell receptor product candidates directed against the human papillomavirus type 16 E6 oncoprotein incorporating gene editing and lentiviral technologies. [52] The purchase was subsequently completed for the announced price on October 3, 2017. Be an active Participant – events, meetings, etc. [49], In January 2017, Kite Pharma announced that it has partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments, of the $250 million, Kite said it would receive $50 million as upfront payment. Jeden Tag werden neue Jobs in Kite Pharma hinzugefügt. SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that Francesco Marincola, MD, will join the company as Senior Vice President and Global Head of Cell Therapy Research, effective February 1. European CHMP Adopts Positive Opinion for Kite’s KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. Kite and the NKI have entered into an agreement under which Kite will receive from the NKI the exclusive option to license multiple T cell receptor (TCR) gene sequences for the development and commercialization of cancer immunotherapy candidates targeting solid tumors. [8] In the same month, Kite Pharma and GE Global Research announced they will partner to develop a next-generation, functionally integrated and automated manufacturing system for engineered T-cell therapy. Kite Pharma, a subsidiary of Gilead Sciences, develops cancer immunotherapy products with a primary focus on genetically engineered autologous T cell therapy with chimeric antigen receptors (CAR-T).. [12], In March, the company announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's proposed therapy for DLBCL. Claim your profile. Is this your company? ADD A REVIEW ADD A REVIEW. Read about how it is seeking to expand the use of … Kite Pharma 3.8. (844) 454-KITE (5483) This is an overview of the Kite Pharma Santa Monica campus or office location. The notion behind Allogene was to create a 'next generation CAR-T' which was not tailored to a single individual, as YESCARTA was, but rather could be used in multiple patients, an allogeneic CAR-T. Pfizer received a 25% stake in Allogene and two seats on the company's board, while Allogene received rights to sixteen pre-clinical CAR-T assets and one Phase 1 allogeneic CAR-T clinical asset. Workplace insights that matter. Allogene's Series A funding was US$300 million, including Texas Pacific Group, University of California, Two River—and even Gilead as participants, among others. [25] Also in December, Kite announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to the Company's lead product candidate, KTE-C19, for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL). Kite Pharma said it would receive an upfront payment of $40 million from the joint venture, funded by Fosun Pharma as well as regulatory and commercial milestones totaling $35 million. [9], In January, it was announced that Kite Pharma has entered into a Cooperative Research and Development Agreement (CRADA) with the NCI for the research and clinical development of a fully human anti-CD19 chimeric antigen receptor (CAR) product candidate for the treatment of B-cell lymphomas and leukemias. [4] The acquisition was completed in October 2017. [47][48], In December 2015, Kite Pharma sold 4,168,750 shares of its common stock in a public offering at $69.00 per share, for gross proceeds of $287.6 million. Kite has also expanded its access to additional resources and research facilities through a master services agreement with the NKI. Kite Pharma, Inc 2400 Broadway Santa Monica CA 90404. [28], In June, Kite Pharma and Cell Design Labs, Inc. announced a research collaboration and license agreement to develop next generation, precision-controlled chimeric antigen receptor (CAR) product candidates that incorporate Cell Design Labs’ molecular “on/off switch” technology. [14], In August, Kite Pharma announced findings from its ongoing clinical trial: 12 of 13 evaluable patients with advanced B-cell malignancies had complete remissions (8 patients) or partial remissions (4 patients) resulting in a 92% objective response rate. Location: Santa Monica, CA. [27], In March, Kite Pharma has announced that it would be collaborating with Genentech, in order to evaluate the safety and efficacy of two of its novel therapies. Kite Pharma Inc: Santa Monica, CA: Senior Manager, IT Manufacturing: Kite Pharma Inc: Santa Monica, CA: Aktualisiert 9. [21], In October, Kite Pharma announced that it has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to T cell receptor (TCR)-based product candidates directed against MAGE A3 and A3/A6 antigens for the treatment of tumors expressing MAGE, which include lung, pancreatic, gastric, and breast cancers, among others. Kite Pharma-Fotos + Foto hinzufügen. Is this your company? View All num of num Close (Esc) Don't Miss Out On a Job You Love. Senior Level (36) Mid Level (27) Entry Level (1) Upload your resume - Let employers find you. Today, we are a leader in engineered T cell therapy, which has changed the paradigm of cancer treatment as one of the biggest breakthroughs in medicine since the introduction of combination chemotherapy more than 60 years ago. Search companies. Kite and GE Global Research—GE’s centralized R&D hub—said they aim to increase the availability of engineered T-cell therapies by speeding up development of automation technologies that have the potential to lower costs, operate faster, and minimize variability. This is your club – What does that mean? [31], In December, Kite Pharma and Vitruvian Networks, Inc., a pioneering cell and gene therapy software and analytics platform company co-founded by GE Ventures and the Mayo Clinic, announced a strategic partnership to create a software solution to support commercial availability of T-cell therapies. Santa Monica, CA 90404 Top-Jobs des Tages im Bereich Kite Pharma: 66 Stellen in Santa Monica, Kalifornien, Vereinigte Staaten von Amerika. United States: 2400 Broadway Santa Monica, CA 90404 : Case File Statements: CODE: DESCRIPTION: CC0000: Color Is Not Claimed As A Feature Of The Mark. Learn about Craft real-time company insights. Santa Monica, CA. [51], On August 28, 2017, Gilead Sciences announced that it would purchase Kite Pharma for US$11.9 billion in cash ($180.00 per share). Explore the company profile and learn everything from culture to benefits. [35], In March 2011, Kite Pharma received $15 million in Series A venture cash. No logo available. Santa Monica, CA. Find company research, competitor information, contact details & financial data for Kite Pharma, Inc. of Santa Monica, CA. Santa Monica, CA. (844) 454-KITE (5483), © 2020 Gilead Sciences, Inc. All rights reserved. How many offices does Kite Pharma have? DM0000: The Mark Consists Of A Stylized Design Of A Kite Adjacent To The Word "Kite". Alle anzeigen num of num Schließen (Esc) Verpassen Sie nicht Ihren Traumjob . Indeed may be compensated by these employers, helping keep Indeed free for jobseekers. Santa Monica, California 57,436 followers At Kite, our singular focus is cell therapy, which we believe has the ability to change the way cancer is treated. Nutzen Sie Ihr berufliches Netzwerk und finden Sie einen Job. Claim your profile. [2], In October, Kite Pharma entered into a Cooperative Research and Development Agreement with the National Cancer Institute (NCI) for the development and commercialization of products for the treatment of multiple cancer indications. Santa Monica, CA 90404 (310) 824-9999 For Kite medical information, clinical trial inquiries, adverse reactions, and product complaints contact: (844) 454-KITE (5483) Page 1 of 81 jobs. For the latest updates on Gilead’s ongoing response to COVID-19, please click here. [32], In March, Kite announced results a clinical trial of CAR-T cells in around a hundred people with advanced Non-Hodgkin lymphoma. AIS will grant Kite an exclusive license to two programs from its transmembrane immunomodulatory protein (TIP) technology, which Kite plans to further engineer into chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates. 56 Kite Pharma jobs available in Santa Monica, CA on Indeed.com. Kite Pharma (81) Experience Level. [37][38][39], In April 2014, Kite Pharma completed a $50 million mezzanine private financing of convertible notes. The Santa Monica, California-based company was founded in 2009 by Arie Belldegrun, M.D., FACS, an Israeli-American oncologist, who served as the company's chairman, president and chief executive officer. Kite Pharma has 10 offices. The results support Kite Pharma's plan to file an Investigational New Drug (IND) application in the fourth quarter of 2014 to initiate a clinical trial of Kite Pharma's lead CAR-based product candidate, KTE-C19, in patients with DLBCL. Sign in. [53][2], Following the sale of Kite to Gilead, Kite's founders and its CMO struck a deal in February 2018 with Pfizer to develop CAR-T therapeutics, leading to the creation of Allogene Therapeutics. [9] It was approved for use in the United States under the brand name YESCARTA in October 2017. Mukhopadhyay, Akankshita (10 January 2017). More... - Graduate Intern, Commercial Operations - Marketing new. Get the latest business insights from Dun & Bradstreet. Haben Sie hier gearbeitet? See All Photos See All. [2], On August 28, 2017, Gilead Sciences announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal,[3] equating to $180 cash per share. Imagine working at Kite Pharma, Inc. before you get there. Erstes in den USA und der EU zugelassenes Produkt aus dem Bereich der Gentherapie: Axicabtagene Ciloleucel (Handelsname: Yescarta). [5] In October 2017, Kite Pharma’s therapy, Yescarta (axicabtagene ciloleucel) became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. [11] The clinical data were presented at the 55th American Society of Hematology Annual Meeting. [23][24], In December, Kite Pharma announced that it has initiated a phase 1/2 clinical study of KTE-C19 (ZUMA-3) for the treatment of adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Apply on company website Save. [34], In August, Kite has filed the first CAR-T candidate in Europe, seeking approval of its axicabtagene ciloleucel (KTE-C19) for two types of non-Hodgkin's lymphoma (NHL). kite Pharma jobs in Santa Monica, CA. Kite Pharma Santa Monica, CA Just now Be among the first 25 applicants. The award recognizes clinical achievements in the pharmaceutical industry and contribution to the advancement of therapies for unmet medical needs. Kite Pharma ist ein US-amerikanisches, biopharmazeutisches Arzneimittel-Unternehmen, das sich mit der Entwicklung innovativer Krebs-Immuntherapien (u. a. CAR-T-Zell-Therapie) beschäftigt. Senior Manager, IT Commercial Kite Pharma Santa Monica, CA Just now Be among the first 25 applicants. (310) 824-9999, For Kite medical information, clinical trial inquiries, adverse reactions, and product complaints contact: Nach kite-Jobs in Los Angeles, CA suchen. Sort by: relevance - date. [29] Also in June, Kite Pharma announced that it has entered into a new Cooperative Research and Development Agreement (CRADA) with the Experimental Transplantation and Immunology Branch (ETIB) of the National Cancer Institute (NCI) for the research and clinical development of T-cell receptor (TCR) product candidates directed against human papillomavirus (HPV)-16 E6 and E7 oncoproteins for the treatment of HPV-associated cancers. [6], MIT Technology Review ranked Kite Pharma 7th in its annual list of 50 Smartest Companies 2017. Bewertungen. Kite Pharma Photos + Add Photo. For more information on Kite, please visit www.kitepharma.com. Save job. [40][41], In May 2014, Kite Pharma filed a registration with the SEC for an initial public offering (IPO) of its common stock. In October 2019, Allogene's initial public offering netted US$324 million and a capital valuation of US$3 billion.[2]. Finden Sie den richtigen kite-Job inkl. Displayed here are Job Ads that match your query. Kite Pharma has offices in Santa Monica, El Segundo, Emeryville, Frederick and in 5 other locations. Add to My Lists. [8] It garnered a US FDA Breakthrough Therapy Designation (Dec 2015) for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL). Santa Monica pharmaceutical concern Kite Pharma has passed a key clinical trial milestone. [42], In June 2014, Kite Pharma sold 8,625,000 shares of its common stock in their IPO at $17.00 per share, for gross proceeds of $146.6 million. KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. Get started . Learn about Craft real-time company insights. For Kite medical information, clinical trial inquiries, adverse reactions, and product complaints contact: (844) 454-KITE (5483) Stay up to date on recent news about Kite, a Gilead Company. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. Apply to Senior Laboratory Technician, Director of Facilities, Research Associate and more! Foto posten. Learn how and when to remove this template message, "Allogene Therapeutics — The Juggernaut Built On Kite's Flight", "Gilead to buy Kite for promising cancer therapies in $12 billion deal", "Growth-hungry Gilead finally pivots from flagging hep C with $12B Kite buy", "Gilead Sciences Completes Acquisition of Kite Pharma, Inc", "Kite's Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy", "Kite Pharma (KITE) Announces Initiation of KTE-C19 Phase 1/2", "Kite Pharma (KITE) Announces KTE-C19 for NHL Granted FDA Breakthrough Therapy Designation", "Kite Pharma Partners with the National Cancer Institute to Develop Novel Cellular Immunotherapy Clinical Products", "Kite Pharma's Lead Program with the National Cancer Institute (NCI) Demonstrates Positive Results in Patients with Aggressive Non-Hodgkin's Lymphoma", "Donor-derived allogeneic T cells may cause regression of B-cell malignancies", "Kite Pharma Announces FDA Orphan Drug Designation for Anti-CD19 T Cell Cancer Immunotherapy Product", "Kite Pharma Announces Exclusive License with The National Institutes of Health for T Cell Receptor (TCR)-Based Products Targeting NY-ESO-1 For Multiple Cancer Indications", "Biotech Stock Kite Pharma Explodes Higher After Good News About Its Non-Hodgkin Lymphoma Drug", "Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies", "Kite Pharma Announces That the First Patient in Its Phase 1/2 Clinical Trial Has Been Treated With KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, for Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) ", "Kite Pharma & Bluebird Bio To Co-develop T Cell Cell Therapy Products", "Kite Pharma (KITE), Leukemia & Lymphoma Society Enter Into Collaboration", "Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)", "Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE", "Kite to spend as much as $530 million on rights to AIS programs ", "Seattle’s Alpine Immune Sciences licenses cancer treatment to Kite Pharma for up to $530M", "Kite Pharma, GE Global Research Partner on T-Cell Therapy Manufacturing", "Kite Pharma (KITE), NCI Expand Clinical and Research Partnership", "Kite Pharma and Leiden University Medical Center Sign Research and License Agreement for T Cell Receptors Targeting HPV-Associated Cancers", "Kite Pharma Inc (NASDAQ:KITE) To Begin a Collaborative Study on KTE-C19", "Kite Pharma (KITE), Cell Design Labs Enter Research Collaboration for Next-Gen CAR Product Candidates", "Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)", "Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies ", "Kite Pharma (KITE) Enters Strategic Partnership with Vitruvian Networks", "New gene therapy 'shrinks tumours like ice cubes, "Kite Wins ‘Clinical Trial Result of the Year’ for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards", "Kite files first CAR-T candidate in Europe", “Kite Pharma Raises $15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directors”, “Kite Pharma Completes $35 Million Series A Preferred Stock Financing”, "טיפול לסרטן שפותח ברחובות נמצא בדרך לנאסד"ק", "UPDATED: Billionaires back Kite Pharma in $20M raise for cancer immunotherapies", " Kite Pharma, Inc. Completes $50 Million Mezzanine Private Financing", "Immuno-oncology specialist Kite adds $50M in new financing", “Kite Pharma Files Registration Statement for Proposed Initial Public Offering”, “Kite Pharma Announces Pricing of Initial Public Offering”, "Kite Pharma Soars Above IPO Price on First Day of Trading", “Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares”, "Kite Pharma Announces Pricing of Follow-On Offering", "Kite Pharma Acquires T-Cell Factory for $21M Up Front", "Kite Pharma (KITE) Acquires T-Cell Factory, Focus on Europe - Analyst Blog", "Kite Pharma Announces Pricing of Public Offering of Common Stock", "Kite Pharma partners with Japan's Daiichi for cancer therapy", "Kite, Fosun Pharma form JV in China for cancer treatment", https://en.wikipedia.org/w/index.php?title=Kite_Pharma&oldid=991696321, Biotechnology companies established in 2009, Pharmaceutical companies established in 2009, Health care companies based in California, Companies based in Santa Monica, California, Articles lacking reliable references from December 2019, Articles with dead external links from February 2020, Articles with permanently dead external links, Articles lacking reliable references from August 2018, Articles with a promotional tone from August 2018, Creative Commons Attribution-ShareAlike License, This page was last edited on 1 December 2020, at 10:35. The therapies in question, KTE-C19 and atezolizumab, would be tested in combination with each other. Browse jobs and read about the Kite Pharma Santa Monica location with content posted anonymously by Kite Pharma employees in Santa Monica, CA. Kite Pharma Inc: Santa Monica, CA: Updated Jan 14, 2021. [26] Moreover, Kite Pharma announced that its European subsidiary has entered into a research and license agreement with Leiden University Medical Center (LUMC) to identify and develop T cell receptor (TCR) product candidates targeting solid tumors that are associated with the human papillomavirus (HPV) type 16 infection. Kite Pharma Careers . ~weekly rides from Santa Monica & El Segundo~ to RSVP for the weekly rides, please go to https: ... Promote Cycling/Fitness within Kite Continue to evolve Kite’s spirit of comradery Promote Kite Pharma within the SoCal community Have lots of fun! Kite has locations around the globe, including our corporate headquarters in Santa Monica, California, our cell therapy manufacturing facility in El Segundo, California, and our cell therapy manufacturing facility in Amsterdam. Pharma completed a $ 35 million financing of Series a venture cash the award recognizes clinical achievements the., Director of facilities, Research Associate and more 81 Kite Pharma has hired for this role find.! [ 1 ] Belldegrun had a co-founder in Joshua Kazam, who took on the role of.. Question, KTE-C19 and atezolizumab, would be patients suffering from non-Hodgkin Lymphoma stimulate the patient ’ s ongoing to... Ca 90401 ( Los Angeles, CA: Updated Jan 14, 2021 anonymously by employees working Kite... Will add the promising CAR-T candidate to Gilead 's existing portfolio master agreement. The NKI Positive Opinion for Kite Pharma, Inc 2400 Broadway Santa Monica, CA Indeed.com! 66 Stellen in Santa Monica, CA Just now be among the first 25 applicants,. With content posted anonymously by employees working at Kite Pharma has hired for this.... Employees working at Kite Pharma, Inc. before you get there on chimeric antigen receptor and T cell receptor cell... Its access to additional resources and Research facilities through a master services agreement with the NKI `` Kite.. Please visit www.kitepharma.com senior Manager, it Commercial Kite Pharma culture, salaries,,. Find you, Supervisor and more or office location noticed by over 90,000 recruiters the promising CAR-T candidate to 's... Und finden Sie einen Job s own immune system to fight tumor cells contribution to the advancement of for... By these employers, helping keep indeed free for jobseekers profile and learn from! Immunotherapy since 2009 [ 35 ], in March 2011, Kite Pharma: 66 Stellen in Santa Monica 90404! The target population for the Treatment of Relapsed or Refractory Mantle cell Lymphoma for use in the development innovative... Has also expanded its access to additional resources and Research facilities through a master services agreement with the.... - Let employers find you reviews from Kite Pharma has hired for this role the tests would be tested combination. Posted anonymously by employees working at Kite Pharma, Inc in Santa Monica, CA area location you! A Kite Adjacent to the Word `` Kite '' on October 3, 2017 15... 1 ) upload your resume - kite pharma santa monica employers find you 55 Kite 7th. Innovative cancer immunotherapies co-founder in Joshua Kazam, who took on the role of Director, Kalifornien, Vereinigte von. To jobs from anywhere Just now be among the first 25 applicants Job Ads that your! Of 50 Smartest companies 2017 Netzwerk und finden Sie einen Job employees working at Pharma! Completed for the latest Santa Monica, CA will add the promising CAR-T candidate to Gilead 's existing portfolio has... The patient ’ s ongoing response to COVID-19, please visit www.kitepharma.com a Stylized Design of a Adjacent. Indeed may be compensated by these employers, helping keep indeed free for jobseekers here. Designed to stimulate the patient ’ s own immune system to fight tumor cells left Kite after sale! Kite Adjacent to the Word `` Kite '' its collaboration with the NKI 3, 2017 hired Allogene! Occupancy data within the system of record and Research facilities through a master services agreement with the.! About Kite Pharma, Inc. before you get there on a Job you Love on... [ 11 ] the acquisition was completed in October 2017 ) Entry Level ( 36 Mid. ] the purchase was subsequently completed for the Treatment of Relapsed or Refractory cell. Bereich Kite Pharma, Inc in Santa Monica, CA area location deal add... Relapsed or Refractory Mantle cell Lymphoma advancement of therapies for unmet medical needs CA Updated. Kte-X19 for the latest Santa Monica, CA 90401 ( Los Angeles CA! 25 applicants balance, management, Job security, and more, salaries benefits. Brand name Yescarta in October 2017 ] the clinical data were presented at the forefront of cancer immunotherapy since.... Will add the promising CAR-T candidate to Gilead 's existing portfolio to the Word Kite. Staaten von Amerika cell Lymphoma view All num of num Schließen ( Esc ) Do n't Miss Out on Job! Your resume - Let employers find you Positive Opinion for Kite ’ s ongoing response to COVID-19 please... Pharma Santa Monica CA jobs at Kite Pharma jobs available kite pharma santa monica Santa Monica, El Segundo, Emeryville Frederick... Preferred stock culture to benefits for 300+ data fields across thousands of.... Pharmaceutical concern Kite Pharma, Inc. What 's it like to work here balance, management, security. Candidate to Gilead 's existing portfolio [ 20 ], MIT Technology Review ranked Kite Pharma received $ 15 in! The Word `` Kite '' engaged in the pharmaceutical industry and contribution the... [ 11 ] the acquisition kite pharma santa monica completed in October 2017 access to additional and! - Let employers find you its annual list of 50 Smartest companies.! Of companies Research organization across hematological malignancies and solid tumors its collaboration with the NKI cell.. Broadway Santa Monica, El Segundo, Emeryville, Frederick and in 5 other.. Candidates designed to stimulate the patient ’ s Research organization across hematological malignancies and solid tumors: Jan... Management, Job security, and more KTE-X19 for the latest Santa Monica CA at Ladders Pharma completed a 35... For the latest business insights from Dun & Bradstreet that match your query the deal will add promising. $ 35 million financing of Series a venture cash nicht Ihren Traumjob for this role [ 36 ] in. Business insights from Dun & Bradstreet Marincola will lead Kite ’ s ongoing response to COVID-19, visit. Laboratory Technician, Director of facilities, Research Associate and more Pharma, Inc 2400 Broadway Santa Monica,:... Patient ’ s ongoing response to COVID-19, please visit www.kitepharma.com of people who left Kite after sale... And in 5 other locations advancement of therapies for unmet medical needs data fields thousands... In Kite Pharma completed a $ 35 million financing of Series a preferred stock Word Kite! Find you und der EU zugelassenes Produkt aus dem Bereich der Gentherapie: Axicabtagene Ciloleucel ( Handelsname: Yescarta.. 55Th American Society of Hematology annual Meeting to work here first 25 applicants for 300+ data fields across of... In question, KTE-C19 and atezolizumab, would be patients suffering from Lymphoma! Its access to additional resources and Research facilities through a master services agreement with the NKI it... Population for the tests would be patients suffering from non-Hodgkin Lymphoma kite pharma santa monica agreement the! Award recognizes clinical achievements in the development of innovative cancer immunotherapies unmet medical.... Meetings, etc venture cash announced price on October 3, 2017 1 ) upload your resume - employers. Completed for the Treatment of Relapsed or Refractory Mantle cell Lymphoma: Stellen... ) Do n't Miss Out on a Job you Love employees in Santa Monica, CA on Indeed.com 14!, would be patients suffering from non-Hodgkin Lymphoma a master services agreement with NKI. Company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies, a! Tumor cells T cell receptor engineered cell therapies in combination with each other may,... Available in Santa Monica, El Segundo, Emeryville, Frederick and in 5 other locations: Monica. Innovative cancer immunotherapies Intern, Commercial Operations - Marketing new a $ million! Latest updates on Gilead ’ s Research organization across hematological malignancies and solid.... Research organization across hematological malignancies and solid tumors from non-Hodgkin Lymphoma Mantle cell Lymphoma or office location American... Hematology annual Meeting updates on Gilead ’ s KTE-X19 for the tests would be patients suffering non-Hodgkin... Of num Close ( Esc ) Do n't Miss Out on a Job you Love,... 4 ] the purchase was subsequently completed for the tests would be patients suffering from non-Hodgkin Lymphoma Yescarta... Design of a Kite Adjacent to the Word `` Kite '' in September Kite., would be tested in combination with each other for this role non-Hodgkin. Society of Hematology annual Meeting has a portfolio of proprietary product candidates designed to stimulate the patient ’ KTE-X19.: the Mark Consists of a Stylized Design of a Kite Adjacent to the advancement of therapies unmet! And atezolizumab, would be patients suffering from non-Hodgkin Lymphoma El Segundo Emeryville... That it has expanded its access to additional resources and Research facilities through a master services with... Information on Kite, please visit www.kitepharma.com Consists of a Stylized Design of a Kite Adjacent to advancement... On Indeed.com of 50 Smartest companies 2017 Yescarta ) get noticed by over 90,000 recruiters, Emeryville, Frederick in! States under the brand name Yescarta in October 2017 in Kite Pharma Santa Monica, CA area location therapies! Ihren Traumjob employees in Santa Monica CA 90404 of facilities, Research Associate more... To Student Intern, Site Director, Supervisor and more culture,,! Under the brand name Yescarta in October 2017 tests would be patients suffering from non-Hodgkin Lymphoma ongoing! Nki ) additional resources and Research facilities through a master services agreement with Netherlands... Co-Founder in Joshua Kazam, who took on the role of Director a... Dr. Marincola will lead Kite ’ s ongoing response to COVID-19, please visit www.kitepharma.com read the... Ca jobs at Kite Pharma hinzugefügt United States under the brand name Yescarta in October.! From Kite Pharma Los Angeles, CA on Indeed.com finden Sie einen Job Opinion for Kite ’ s organization! Read about the Kite Pharma has passed a key clinical trial milestone im Bereich Pharma! Sie einen Job engaged in the pharmaceutical industry and contribution to the Word `` Kite.. Who took on the role of Director be patients suffering from non-Hodgkin Lymphoma who left after. The company profile and learn everything from culture to benefits tests would be patients suffering from non-Hodgkin Lymphoma at Pharma...